Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Dear Editor,—As the coronavirus disease 2019 (COVID-19) pandemic ensues, studies have shown association between procalcitonin (PCT) with severity and prognosis of COVID-19 patients [1,2]. Studies have also shown association between bacterial coinfection with severity and prognosis of COVID-19 patients [2,3]. To the best of our knowledge, there has been no study on direct association between PCT and bacterial coinfection in COVID-19 patients. Many studies showed PCT that can accurately differentiate culture-negative and culture-positive sepsis from non-infectious diseases, thus making it a biomarker in diagnosis of bacterial sepsis [4]. An increased level of PCT in COVID-19 patients especially in severe cases would be assumed as bacterial coinfection. Could PCT level increase in severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infection without bacterial coinfection? Could it be that PCT is part of human immunological response to SARS-CoV-2, especially in severe cases of COVID-19? Here we describe the potential immunological mechanisms in which SARS-CoV-2 can increase the PCT level in the absence of bacterial coinfection.

Previous studies found that in severe acute respiratory syndrome (SARS) PCT level did not increase, contrary to bacterial and fungal pneumonia where the PCT level increased. SARS and COVID-19 are caused by coronavirus that share similar structure, so it is speculated that both coronavirus would render similar human immune system response and PCT level would not increase in COVID-19 unless there is bacterial coinfection [1]. A study showed that bacterial coinfection in COVID-19 was associated with increased mortality [2]. Bacterial coinfection increases the degree of systemic inflammation, thus increasing the severity of the disease and worsen the prognosis [5]. It was suggested that in COVID-19 patients PCT levels appeared to depend on disease severity, and that bacterial coinfection might be present in many patients, especially with severe and critical disease [1,6].

PCT is a polypeptide precursor of the hormone calcitonin, which is mainly produced by the C-cells of the thyroid gland and other cells such as monocytes. PCT production increases in the presence of cytokines caused by bacterial infection and lipopolysaccharides (LPS). It does not increase in sterile inflammation or viral infection [4]. The elevated PCT is sustained by the increased levels of interleukin (IL)–1β, tumor necrosis factor (TNF)-α and IL-6 in bacterial infection. In viral infection interferon (IFN)-γ level is increased, which inhibited PCT production [6]. PCT production in monocytes is regulated by microRNA (miR)–125b via signal transducer and activator of transcription 3 (STAT3) [7]. After LPS stimulation on monocytes, miR-125b level decreased, STAT3 and phosphorylated STAT3 level increased, promoting the expression of PCT [8].

There are new findings on the SARS-CoV-2 proteins and their role in the pathogenesis of COVID-19 based on studies on SARS-CoV-1. Several SARS-CoV-1 and SARS-CoV-2 proteins have similar antagonist activity against IFNs and the downstream Janus kinase (JAK)-STAT signaling pathways based on a comparative genetic structural study [9]. SARS-CoV-2 proteins inhibit the function of STAT1 and IFNs, and cause a compensatory activation of STAT3 in human cells infected by SARS-CoV-2 [10]. SARS-CoV-2 proteins that have an increased anti-IFN-I activity are open reading frame (ORF) 3b variant (56 aa), ORF6, and non structural protein 1 (NSP1) [10,11]. As the SARS-CoV-2 inhibits STAT1 phosphorylation, IFN-stimulated gene transcription in monocyte-derived dendritic cells and macrophages increases [12]. After ORF6 or NSP1 impair STAT1 function, the compensatory STAT1-independent pathways commences, making way to STAT3-dependent transcriptional pathways (Fig. 1(A)). STAT3 also have been shown to inhibits the STAT1-mediated IFN-1 response. This alternative STAT3 transcriptional pathways are responsible to most pathology found in severe COVID-19 patients such as increased coagulopathy/thrombosis, proinflammatory state, and T cell lymphopenia [10]. As mentioned above, in most viral infection the level of IFNs are increased, which caused inhibition of PCT production [6]. On the contrary, SARS-CoV-2 proteins inhibit the function of IFNs and up-regulate STAT3 signaling in monocytes, that would result in the increased PCT production. The increase of STAT3 in COVID-19, would lead to increased PCT production (Fig. 1(B)).

There is evidence of impaired function of monocytes in COVID-19 that was caused by enhanced viral growth due to non-neutralizing
immunoglobulin M (IgM), IgG, complement, hypoxia, loss of antiviral function of macrophages due to lymphopenia, and hyperactivation of immature monocytes. Monocyte’s impaired function and its dysregulated secretory production resulted in increased PCT production in COVID-19 [13].

A study on the role of STAT3 in regulating angiotensin converting enzyme 2 (ACE2) expression revealed that STAT3 has two isoform: STAT3α which is the main isoform, and STAT3β which encodes a truncated STAT3 protein. STAT3α causes increased ACE2 mRNA and protein expression, and STAT3β causes decreased ACE2 mRNA and protein levels [14]. There is still no evidence on which STAT3 isoform that is increased in COVID-19. If the STAT3α isoform is increased, ACE2 mRNA and protein expression will also increased, leading to more entry of SARS-CoV-2 into other cells.

As a summary, we could say that STAT3-dependent transcriptional pathways in SARS-CoV-2 infection will increase STAT3 level, and the viral loads will rise rapidly. As a result, we expect that STAT3 protein levels [14]. There is still no evidence on which STAT3 isoform is increased in COVID-19. If the STAT3α isoform is increased, ACE2 mRNA and protein expression will also increased, leading to more entry of SARS-CoV-2 into other cells. The manuscript has been read and approved by the author. The requirements for authorship as stated earlier in this document have been met.

The author believes that the manuscript represents honest work.

References

[1] Liu Z-M, Li J-P, Wang S-P, Chen D-Y, Zeng W, Chen S-C, Huang Y-H, Huang J-L, Long W, Li M, Gao R-F, Guo L, Wu X-H. Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19. Int J Med Sci 2020;17(16):2468–76. doi: 10.7150/ijms.48306.

[2] Martins-Filho PR, Tavares CSS, Santos VS. Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data. Eur J Intern Med 2020;76:97–9. doi: 10.1016/j.ejim.2020.04.043.

[3] Zhang H, Zhang Y, Wu L, Li Y, Zhou X, Li X, Chen H, Guo M, Chen S, Sun F, Mao R, Qiu C, Zhu Z, Ai J, Zhang W. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg Microbes Infect 2020;9(1):1958–64. doi: 10.1080/22221751.2020.1812437.

[4] Anand D, Das S, Ray S, Bhargava S, Srivastava L, M. Interrelationship between procalcitonin and organ failure in sepsis. Indian J Clin Biochem 2014;29:93–6. doi: 10.1007/s12291-013-0326-z.

[5] Chen X, LiaoB Cheng L, Peng X, Xu X, Li Y, Tu T, Li J, Zhou X, Ren B. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol 2020;104:7777–85. doi: 10.1007/s00253-020-10814-6.

[6] Lipp G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta 2020;505:190–1. doi: 10.1016/j.cca.2020.03.004.

[7] Zhang F, Fan X, Bai Y, Liu J, Zheng M, Chen J, Liu Y, Chen Z, Zhu J. miR-125b regulates procalcitonin production in monocytes by targeting Stat3. Microbiol Infect 2016;18:102–8. doi: 10.1016/j.micinf.2015.09.027.

[8] Le X, Chen T, Xun K, Ding T. Expression of the long intergenic non-coding RNA (lincRNA) of the NED25 gene modulates the microRNA-125b, STAT3, nitric oxide, and procalcitonin signaling pathways in patients with sepsis. Med Sci Monit 2018;24:4555–66. doi: 10.12659/MSM.907496.

[9] Sardar R, Satish D, Birla S, Gupta D. Comparative analyses of SARS-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to host-virus interaction and pathogenesis. bioRxiv 2020. doi: 10.1016/j.cell.2020.03.011586.

[10] Matsuyama T, Kubli SP, Yoshinaga SK, Klaus Pfeffer K, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ 2020;1:1–17. doi: 10.1038/s41418-020-00633-7.
[11] Konno Y, Kimura I, Uriu K, Fukushi M, Irie T, Koyanagi Y, Sauter D, Gifford RJ, Consortium USFQ-COVID19, Nakagawa S, Sato K. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant. Cell Rep 2020;32(12):108185. doi: 10.1016/j.celrep.2020.108185.

[12] Yang D, Chu H, Hou Y, Chai Y, Shuai H, Lee AC-Y, Zhang X, Wang Y, Hu B, Huang X, Yuen TT-T, Cai J-P, Zhou J, Yuan S, Zhang AJ, Chan JF-W, Yuen K-Y. Attenuated interferon and pro-inflammatory response in SARS-CoV-2-infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. J Infect Dis 2020;222(5):734–45. doi: 10.1093/infdis/jiaa356.

[13] Martinez FO, Combes TW, Orsenigo F, Siamon Gordon S. Monocyte activation in systemic Covid-19 infection: assay and rationale. EBioMedicine 2020;59:102964.

[14] Shamir I, Abuthul-Amital M, Abbas-Eghbariya H, Pasmanik-Chor M, Paret G, Nevo-Caspi Y. STAT3 isoforms differentially affect ACE2 expression: a potential target for COVID-19 therapy. J Cell Mol Med 2020;00:1–5.